Who makes Femoston Conti?

Femoston Conti is developed by Royal Brompton & Harefield NHS Foundation Trust.

What development phase is Femoston Conti in?

Femoston Conti is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Femoston Conti

Royal Brompton & Harefield NHS Foundation Trust · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Femoston Conti
Also known as	Femoston Conti 0.5mg/2.5mg film-coated tablets versus
Sponsor	Royal Brompton & Harefield NHS Foundation Trust
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy (PHASE4)
The Effects of Tualang Honey on Postmenopausal Women (PHASE2, PHASE3)
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Femoston Conti CI brief — competitive landscape report
Femoston Conti updates RSS · CI watch RSS
Royal Brompton & Harefield NHS Foundation Trust portfolio CI